DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ARESTIN
» See Plans and Pricing
All Clinical Trials for Arestin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00371332 | Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis | Completed | OraPharma | Phase 3 | 2004-01-01 | The purpose of this study is to measure the antimicrobial effects of Arestin in subjects with moderate to advanced periodontal disease |
| NCT01517334 | Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation) | Completed | OraPharma | Phase 3 | 2012-05-01 | The objective of the study is to evaluate the safety, effectiveness and anti-microbial effects of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites. |
| NCT01531582 | Minocycline in the Treatment of Angelman Syndrome | Unknown status | University of South Florida | N/A | 2012-04-01 | There is mounting evidence to suggest that a treatment for Angelman syndrome is not just possible, but probable. The lack of known molecular targets associated with AS has hampered the development of specific therapeutics. However, a recent surge of potential therapeutics for other disorders associated with cognitive disruption has begun to be used in human clinical trials. The molecular modes of action for many of these new therapeutic agents have correlates to counter the molecular defects observed in AS. One such agent is minocycline (MC), a drug traditionally used as an antibiotic. This compound administered to a mouse model of AS showed a significant decrease in motor deficit and an increase in long term potentiation. The investigators believe a similar result will be observed when minocycline is administered to the AS patient and may lead to the development of an effective AS therapeutic. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Arestin
Condition Name
Clinical Trial Locations for Arestin
Trials by Country
Clinical Trial Progress for Arestin
Clinical Trial Phase
Clinical Trial Sponsors for Arestin
Sponsor Name
